Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 164

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

CAR T therapies in multiple myeloma: unleashing the future

Open access
Sheykhhasan, Mohsen, Ahmadieh-Yazdi, Amirhossein, Vicidomini, Rosario, Poondla, Naresh, Tanzadehpanah, Hamid, Dirbaziyan, Ashkan, Mahaki, Hanie, Manoochehri, Hamed, Kalhor, Naser, Dama, Paola · 2024 · Cancer Gene Therapy

Abstract

In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that have revolutionized the landscape of care for cancer patients. While traditional pillars such as surgery, chemotherapy, and radiation therapy have long been available, a cutting-edge therapeutic approach called CAR T-cell therapy has emerged as a game-changer in treating multiple myeloma (MM). This novel treatment method complements options like autologous stem cell transplants and immunomodulatory medications, such as proteasome inhibitors, by utilizing protein complexes or anti-CD38 antibodies with potent complement-dependent cytotoxic effects. Despite the challenges and obstacles associated with these treatments, the recent approval of the second FDA multiple myeloma CAR T-cell therapy has sparked immense promise in the field. Thus far, the results indicate its potential as a highly effective therapeutic solution. Moreover, ongoing preclinical and clinical trials are exploring the capabilities of CAR T-cells in targeting specific antigens on myeloma cells, offering hope for patients with relapsed/refractory MM (RRMM). These advancements have shown the potential for CAR T cell-based medicines or combination therapies to elicit greater treatment responses and minimize side effects. In this context, it is crucial to delve into the history and functions of CAR T-cells while acknowledging their limitations. We can strategize and develop innovative approaches to overcome these barriers by understanding their challenges. This article aims to provide insights into the application of CAR T-cells in treating MM, shedding light on their potential, limitations, and strategies employed to enhance their efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41417-024-00750-2

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 164

Metadata

Authors
Sheykhhasan, M., Ahmadieh-Yazdi, A., Vicidomini, R., Poondla, N., Tanzadehpanah, H., Dirbaziyan, A., Mahaki, H., Manoochehri, H., Kalhor, N., & Dama, P.
Venue
Cancer Gene Therapy
Published
2024-03-04
Volume
31
Issue
5
Pages
667-686
ISSN
  • 0929-1903 (ISSN-L)
  • 1476-5500
OpenAlex
W4392374645
Cited by
164
References
14
FWCI
25.17
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CAR T therapies in multiple myeloma: unleashing the future. https://app.cochat.ai/papers/10.1038/s41417-024-00750-2
The paper
Sheykhhasan, M., Ahmadieh-Yazdi, A., Vicidomini, R., Poondla, N., Tanzadehpanah, H., Dirbaziyan, A., Mahaki, H., Manoochehri, H., Kalhor, N., & Dama, P. (2024). CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Therapy. https://doi.org/10.1038/s41417-024-00750-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.